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mEq/l, respectively. This was reduced to 38.1% (p = 0.009), 
11.9% (p < 0.001), and 2.4% (p = 0.2) on patiromer. Following 
P binder discontinuation, the long interdialytic interval 
mean ± SE serum P numerically increased from 5.8 ± 0.4 to 
7.0 ± 0.5 mg/dl (p = 0.06). On patiromer, P decreased from 
7.0 ± 0.5 to 6.2 ± 0.5 mg/dl (p = 0.04). While on patiromer, fe-
cal P numerically increased by 112 ± 72 mg/day (17%; p = 
0.1792; range –148 to 344 mg/day). No patient discontinued 
patiromer because of adverse events (AEs); none had serious 
AEs.  Conclusions: In 6 hyperkalemic HD patients, patiromer 
decreased serum K and P levels and increased fecal K. 
 © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Hyperkalemia is a common condition found in chron-
ic hemodialysis (HD) patients, being present in nearly 
20% of routine laboratory results from large dialysis pro-
viders  [1] . While often viewed as acute or episodic, these 
increases in serum potassium (K) appear to reflect oscil-
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 Abstract 
 Background: Persistent hyperkalemia (serum potassium (K) 
 ≥ 5.5 mEq/l) is a common condition in hemodialysis (HD) pa-
tients, is associated with increased mortality, and treatment 
options are limited. The effect of patiromer, a gastrointesti-
nal K binder, on serum K was examined in HD patients.  Meth-
ods: Six hyperkalemic HD patients (5 anuric) were admitted 
to clinical research units for 15 days (1 pretreatment week 
and 1 patiromer treatment week) and they received a con-
trolled diet with identical meals on corresponding days of 
pretreatment and treatment weeks. Phosphate (P) binders 
were discontinued on admission. Patiromer, 12.6 g daily (di-
vided 4.2 g TID with meals), was started on the Monday 
morning following the last pretreatment week blood sam-
pling. Serum and 24-hour stool samples were collected daily. 
 Results: Mean ± SE serum K decreased (maximum change 
per corresponding day, 0.6 ± 0.2 mEq/l, p = 0.009) and fecal 
K increased 58% on patiromer compared with the pretreat-
ment week. During the pretreatment week, 69.0, 47.6, and 
11.9% of patients’ serum K values were  ≥ 5.5,  ≥ 6.0, and  ≥ 6.5 
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lations above a persistent hyperkalemia baseline  [2] . Nu-
merous observational studies in HD patients have report-
ed an association between elevated K levels and increased 
morbidity and mortality  [1, 3] . The increased event rate, 
and particularly sudden death, observed in the HD popu-
lation is not evenly distributed over the 7-day week but is 
clustered toward the end of the long interdialytic interval 
and the immediate post dialysis period  [4] . These data 
raise the possibility that hyperkalemia occurring during 
the long interdialytic interval and the acute decreases in 
the serum K concentrations induced by the HD proce-
dure may play a role in the increased event rate and mor-
tality seen in HD patients.
 Patiromer is an FDA-approved, sodium-free, nonab-
sorbed K-binding polymer shown to reduce serum K levels 
in patients with chronic kidney disease (CKD), with and 
without heart failure  [5–8] . Patiromer exchanges calcium 
(Ca) for K in the gastrointestinal tract, primarily in the co-
lon where active K secretion occurs, the pKa of patiromer 
is optimal for ion exchange, and the polymer has the lon-
gest residence time  [9–11] . This phase 2 study was per-
formed early in the clinical development program follow-
ing studies in healthy volunteers. The primary objective of 
this study was to assess the efficacy of patiromer in reduc-
ing the serum K in HD patients and to evaluate the safety 
and tolerability of patiromer in this patient population.
 Methods 
 The study protocol was reviewed and approved by an institu-
tional review board (Copernicus Group, Research Triangle Park, 
N.C., USA) and written informed consent was obtained from each 
patient prior to enrollment. The study was conducted in accor-
dance with the ethical principles of the Declaration of Helsinki and 
in accordance with International Conference on Harmonization/
Good Clinical Practice guidelines.
 Six patients were enrolled and admitted to the clinical research 
unit at 2 sites (Minneapolis, Orlando) on a Sunday and they re-
mained confined throughout the 2-week study (1 pretreatment 
week and 1 patiromer treatment week). Patients received 3 times 
per week HD and were required to have a serum K  ≥ 5.5 mEq/l and 
a Kt/V  ≥ 1.2 for entry into the study. All patients were on a stable 
dialysis prescription, including a stable dialysate K prior to admis-
sion and remained on that same prescription throughout the 
study. All patients were dialyzed on a Monday–Wednesday–Fri-
day schedule and received treatment approximately the same time 
of day throughout the study. On admission, patients were placed 
on a K-, magnesium (Mg)-, Ca-, and Na-controlled diet through-
out the study period with identical meals on corresponding days 
of the pretreatment and patiromer treatment weeks. It was essen-
tial that dietary intake remained unchanged from the time of 
screening through the end of study participation. No food or drink 
other than that provided by the Clinical Research Unit was con-
sumed during the entire study period. On average, the daily K-, 
Mg-, Ca-, and Na-controlled diet provided the following micronu-
trients (mean ± SE): K 2,760 ± 60 mg, Na 2,692 ± 93 mg, Ca 619 ± 
22 mg, Mg 225 ± 27 mg. Any unconsumed food was recorded.
 P binders, Ca supplements, and the polymer-based medica-
tions colesevelam and colestipol were discontinued on admission 
and along with commercially available K-binding resins were not 
allowed during the study period. No subject had received sodium 
polystyrene sulfonate (SPS) in the 30 days preceding study entry. 
All treatments were administered in the Clinical Research Unit 
under the supervision of clinical personnel.
 Serum chemistries were measured on a daily basis (pre-HD on 
HD days). Serum bicarbonate was not measured during the course 
of the study. Only 1 patient produced more than 200 ml of urine 
per day and the ionic content of the urine was not analyzed. Twen-
ty-four-hour stool samples were collected during the entire con-
finement period. Each 24-hour fecal collection was homogenized 
and aliquots were then analyzed for K, Na, Ca, Mg, and P. Change 
from baseline in fecal ion excretion was evaluated by comparing 
the mean daily fecal excretion of the ion during the patiromer 
treatment week (Tuesday–Monday) versus the pretreatment week 
(Tuesday–Monday). Serum measurements were performed at the 
MedTox Laboratory (St. Paul, Minn., USA) and fecal analyses at 
the Battelle Toxicology Northwest (Richland, Wash., USA).
 Electrocardiograms (ECGs) were performed in triplicate daily 
with the patient resting and prior to the morning patiromer dose. 
On HD days, triplicate ECGs were performed prior to HD, at the 
mid-dialysis time point, and 1 h post HD.
 Patiromer, at a total daily dose of 12.6 g/day, was adminis-
tered as 4.2 g TID with meals starting on the Monday morning of 
week 2.
 Statistics 
 Originally, it was planned that 12–24 patients would be as-
sessed, but due to difficulty in the enrolling process, the study was 
stopped after assessment on 6 patients was completed. Due to the 
limited number of patients, the statistical inference testing results 
were conducted only for descriptive purposes. Descriptive statis-
tics were summarized as mean ± SE for continuous variables or as 
proportions for categorical variables unless specified otherwise. 
The protocol had a one-day run-in period on the diet, which is why 
the values on the first Monday of treatment was not analyzed; rath-
er Tuesday–Monday values of the pre-patiromer week was com-
pared to the Tuesday–Monday values of the patiromer treatment 
week. The changes on the corresponding days between pretreat-
ment week and the patiromer treatment week in serum potassium 
and phosphate concentrations were analyzed by paired t test using 
SAS (version 9.4). The proportions of patients in each defined po-
tassium range between the pre-treatment and the patiromer treat-
ment week were analyzed by Fisher’s exact test.
 Results 
 Six patients enrolled and completed all study activities. 
One patient was enrolled in error with a screening K of 
5.1 mEq/l but remained in the study. The mean ± SD age 
was 50 ± 4 (range 44–55) years. Five patients were male 
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and 4 were black. Additional demographic information is 
shown in  table 1 . All 6 patients had extensive comorbid 
illnesses. Concomitant medical conditions present in all 
6 patients at the time of the study in addition to end-stage 
renal disease (ESRD) included hyperkalemia, hyperpara-
thyroidism, anemia, and hyperphosphatemia. In addi-
tion, 4 patients had concurrent hypertension. Patients 
were on multiple medications but were on stable doses for 
at least 15 days prior to the start of the study and through-
out the study. Four patients received a beta-blocker, 2 an 
angiotensin-converting enzyme inhibitor, and 1 an an-
giotensin receptor blocker.
 After 1 day of treatment, the serum K numerically 
decreased on patiromer versus the pretreatment week 
by 0.3  ± 0.3 mEq/l (p  = ns; n  = 6) when comparing 
the  corresponding days of the week. The maximum 
 difference was achieved at day 7 where the patiromer 
treatment serum K was 0.6 ± 0.2 mEq/l lower than 
the  value on the corresponding pretreatment day 
(p = 0.009; n = 6;  fig. 1 ). Online supplemental figure 1 
(for all  online suppl. material, see www.karger.com/
doi/10.1159/000451067) shows individual subjects’ se-
rum K values over time and demonstrates the variabil-
ity of serum K in HD patients, while online supplemen-
tal figure 2 shows the average serum K values for the 
patiromer treatment week versus the pretreatment week 
by treatment day. During the pretreatment week, 69.0, 
47.6, and 11.9% of patients’ daily serum K values were 
 ≥ 5.5,  ≥ 6.0, and  ≥ 6.5 mEq/l, respectively. These propor-
tions were reduced to 38.1% (p  = 0.008), 11.9% (p  < 
0.001), and 2.4% (p = 0.2), respectively, on patiromer 
( fig. 2 ). While on patiromer, fecal K excretion increased 
by 359 ± 113 mg/day (58%; equivalent to 64.4 ± 20.3 
mEq/week) over the pretreatment week (p = 0.02; range 
110–739 mg/day), while fecal Ca increased by 1.3 ± 
0.1 g/day (172%; p < 0.01; range 0.7–1.5 g/day), fecal Na 
Table 1.  Patient demographic and characteristic information
 Patient number
02–0 01 02–003 02–005 02–010 02–016 03–008
Demographic
Age, years 48 55 45 50 53 44
Gender Male Male Female Male Male Male
Race Black Black Black Black White White
BMI, kg/m2 20.4 22.5 29.7 25.4 31.1 31.9
BP systolic, mm Hg 106 130 138 110 117 152
BP diastolic, mm Hg 70 70 88 53 68 98
Pulse, bpm 66 80 94 71 84 90
Laboratory results
Baseline K (pre-HD Monday), mEq/l 5.7 7.0 5.1* 5.6 7.9 6.2
Baseline Ca, mg/dl 8.7 8.9 9.8 9.3 8.9 8.4
Baseline P, mg/dl 5.4 4.7 5.2 5.2 7.5 6.5
Dialysis vintage, months 22.0 71.2 80.7 261.1 46.1 >95.5
ACEi/ARB use (yes/no) Yes Yes Yes No No No
HD prescription
Dialysis time, min 210 210 210 240 240 240
Filter type CT190G CT190G Polyflux 17R Polyflux 210H CT190G F180
Dialysate K, mEq/l 1.5 1.5 3 3 1.5 2
Dialysate Ca, mEq/l 2.5 2.5 2.2 2.5 2.5 2.5
Dialysate bicarbonate, mEq/l 38 38 38 38 38 Not listed
Dry weight, kg 66.2 61 72.3 75.6 94.5 95.5
HD medications
Paricalcitol, μg 3 TIW 4 TIW 7 TIW 9 TIW 2 TIW 0
Epoetin alfa, units 4,400 TIW 3,300 TIW 9,900 TIW 4,400 TIW 2,200 TIW 0
P binders Ca acetate Ca acetate Ca acetate Sevelamer Not listed Ca acetate
ACEi = Angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker;  BMI = body mass index; BP = blood pres-
sure; TIW = 3 times a week.
* Patient enrolled in error with K <5.5 mEq/l.
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numerically increased by 60 ± 35 mg/day (57%; p  = 
0.1434; range –10 to 223 mg/day), fecal Mg numerically 
increased by 42 ± 24 mg/day (21%; p = 0.1429; range –37 
to 110 mg/day), and fecal P numerically increased by 
112 ± 72 mg/day (17%; p = 0.1792; range –148 to 344 mg/
day) (n = 6 for each).
 Serum Ca remained within the normal range through-
out the study ( fig. 3 ). Serum P increased during the pre-
treatment week following the discontinuation of P bind-
ers. The long interdialytic serum P numerically increased 
from (mean ± SE) 5.8 ± 0.4 to 7.0 ± 0.5 mg/dl (p = 0.06). 
During the patiromer treatment week, the long interdia-
lytic serum P decreased from 7.0 ± 0.5 mg/dl to 6.2 ± 0.5 
mg/dl (p  = 0.04;  fig.  3 ). Online supplemental figure 3 
demonstrates that ongoing exposure to patiromer in-
creases the separation between the serum P curves during 
the patiromer treatment versus the pre-patiromer treat-
ment week.
 Safety 
 No patient discontinued the study because of adverse 
events (AEs) and there were no serious AEs. One patient 
had a serum Ca as high as 11.0 mg/dl prior to patiromer 
treatment. On treatment with patiromer, the highest se-
 Fig. 1. Serum K values over time during the 
pretreatment week and the patiromer 
treatment week. HD treatments are indi-
cated by arrows. All patients were admitted 
to the research unit on a Sunday and start-
ed on the controlled diet Monday AM. 
 Fig. 2. The proportion of serum K concen-
trations above the corresponding K value.
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rum Ca in this patient was 10.8 mg/dl. No patient had a 
serum Ca level during the patiromer treatment week that 
was above the levels observed in the pretreatment week. 
No patient developed a serum K <4.0 mEq/l on patiromer 
(lowest recorded serum K = 4.2 mEq/l). Serum Mg re-
mained in the normal range and no patient developed 
clinical symptoms of hypomagnesemia (lowest serum 
Mg = 1.3 mEq/l). There were no individual clinically sig-
nificant abnormal ECG findings and no AEs associated 
with ECG abnormalities at any time point during the 
study. However, all patients had abnormal ECG findings 
at multiple time points in the study that were judged not 
to be clinically significant and that are expected for indi-
viduals on HD.
 Discussion 
 In this metabolic study, daily administration of pati-
romer reduced the levels of both mean serum K and serum 
P in 6 hyperkalemic HD patients. Patiromer treatment de-
creased the proportion of days that patients were hyper-
kalemic compared with the pretreatment week. Despite 
the serum K variability in individual subjects, the differ-
ences in mean serum K between the treatment period and 
the pre-treatment period occurred early and were gener-
ally sustained throughout the treatment period, although 
the difference narrowed over the long interdialytic inter-
val suggesting ongoing K redistribution or accumulation. 
A larger and longer-duration study allowing for dose titra-
tion is needed to further investigate the full effect of pati-
romer on serum K in this patient population. No patient 
discontinued the study for AEs and there were no serious 
AEs. Until recently, treatment options for hyperkalemia 
in HD patients were limited to dietary K restriction, low-K 
dialysate, additional dialysis, or intermittent SPS. All of 
these options have significant limitations in adequately 
dialyzed patients. Lower dialysate K concentrations in-
crease the risk of arrhythmias or sudden death  [12, 13] and 
higher sodium intake has been associated with increased 
interdialytic weight gain and mortality  [14] . Furthermore, 
use of SPS has been associated with increased interdia-
lytic weight gain and higher serum phosphate, bicarbon-
ate and sodium concentrations in HD patients  [15] .
 The finding from this study provides preliminary evi-
dence that daily patiromer, even when administered at a 
low dose (as discussed below), can remove more K than 
what is achieved by lowering the dialysate K by 1 mEq/l 
for 3 treatments/week  [16] and suggests that patiromer 
may be an alternate and potentially safer therapy than 
lowering the dialysate K concentration for dialysis pa-
tients with hyperkalemia. As K normally fluctuates in pa-
tients with CKD  [2], the possibility of minimizing these 
fluctuations and providing safer dialysis with patiromer 
deserves further study. Studies using patiromer in con-
junction with a more physiologic K dialysate are also 
needed to determine if arrhythmic events during and post 
dialysis can be decreased by following such an approach.
 In this study, P binders were stopped at the time of ad-
mission to the clinical research center and serum P levels 
were increased during the pre-treatment week. When 
patiromer was given with meals instead of the phosphate 
binder, the serum P level decreased. The numeric in-
crease in stool P is supportive of a potentially clinically 
 Fig. 3. Serum Ca and P over time in both 
the pretreatment week and during the pat-
iromer treatment week. All P binders were 
stopped on the Sunday of admission.  * p = 
0.04 compared to the Monday (M) value 
just prior to the start of the patiromer treat-
ment week. 
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meaningful effect. The reduction in serum P level seen in 
these patients with the increasing separation with ongo-
ing treatment (online suppl. fig. 3) is in agreement with 
earlier studies in healthy volunteers showing that pati-
romer decreased gastrointestinal phosphate absorption 
as measured by a decrease in urine P on a controlled diet 
 [17] . The reduction in serum P level seen in this study 
may be due to the gastrointestinal binding of P by the Ca 
released from patiromer, leading to less gastrointestinal P 
absorption.
 The mean serum Ca level remained within the normal 
range in these ESRD patients on patiromer. The 1 patient 
with mild hypercalcemia was hypercalcemic during the 
pretreatment period and the peak serum Ca level in this 
patient on patiromer was lower than the peak Ca level 
during the pretreatment period. The increase in stool Ca 
during the patiromer treatment week demonstrates that 
the vast majority of the Ca in patiromer appears in the 
stool bound to the polymer as previously reported  [10] . 
This is consistent with the understanding that the main 
site of Ca-K exchange is in the colon where the efficiency 
of Ca absorption is minimal  [18] . This is also in agree-
ment with studies in healthy controls, where changes in 
urine calcium were used as a measure of intestinal ion 
absorption, which demonstrated that about 73 mg of cal-
cium is absorbed from a daily dose of 25.2 g dose of pati-
romer  [17] .
 The finding that the levels of stool Na and Mg in-
creased, support data that patiromer binds Na and Mg 
within the gastrointestinal tract as measured by a de-
crease in these ions in the urine excreted by healthy adults 
who are given patiromer  [17] . The changes in stool Na are 
such that it suggests that patiromer may bind Na in the 
gastrointestinal tract as previously reported  [17] . Al-
though numerically small, decreased Na absorption could 
be beneficial in this patient population where interdia-
lytic weight gain and ultrafiltration volume have been as-
sociated with adverse outcomes  [19, 20] . While the level 
of serum Mg is often within the normal range in HD, 
some patients have increased serum levels  [21] . While the 
risk or benefits of increased serum Mg in HD patients is 
controversial  [22] , these findings suggest that serum Mg 
should be monitored in HD patients treated with pati-
romer  [5] .
 This study has a few important limitations. Most no-
tably is the small sample size (n = 6) of this study with 
short treatment duration. In addition, serum potassium 
concentrations vary within a patient. Larger and a longer-
duration studies with a randomized controlled design in 
HD patients are needed to confirm the findings in this 
study and to ensure tolerability in this patient population. 
Another limitation of the current study was the non-ran-
domization of the control and treatment weeks. The po-
tential bias of this methodology was somewhat limited by 
the use of the clinical research center. An important 
strength of this study is the controlled dietary conditions, 
along with the consistency of its results (e.g., a decrease in 
serum K accompanied by an increase in stool K, the latter 
most probably ruling out any dietary confounding fac-
tor). Furthermore, only 1 dose strength of patiromer was 
tested in this study. The dose tested, 12.6 g/day, is half of 
the FDA-approved maximum dosage. While the dose 
tested limits our ability to assess tolerability of higher dos-
es in this population, it suggests that greater K and P re-
moval could be achieved with greater doses of patiromer. 
The increase toward baseline in the serum K on the Mon-
day after the last dose of patiromer probably reflects the 
ongoing K burden in these patients and highlights the 
need for studies of longer duration with potential dose 
escalations. Finally, in this study, patiromer was admin-
istered 3 times per day and all P binders were stopped on 
admission. As patiromer is approved for once-per-day 
dosing  [5] , the optimal use of P binders in conjunction 
with patiromer treatment needs further study. This study 
suggests that P binders used 2 times per day with meals 
along with patiromer with the third meal might be a rea-
sonable strategy to maintain adequate P control while al-
lowing for safe and effective lowering of K levels.
 In conclusion, the ability of patiromer to decrease se-
rum K and P levels and increase fecal K, and potentially 
fecal P and Na in HD patients suggests that patiromer 
may have beneficial effects on multiple aspects of abnor-
mal mineral metabolism in HD patients. The unique abil-
ity of patiromer to both lower serum K and bind gastro-
intestinal P, without increasing the daily Na load to HD 
patients, suggests it could play an important role in the 
care of HD patients.
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